You are here:  > Browse Articles


The application of prophylactic antibodies for rhinovirus infections

Riccardo Privolizzi, Roberto Solari, Sebastian L Johnston, Gary R McLean

Corresponding author name: Gary R McLean
Corresponding author e-mail:

Citation: Antiviral Chemistry & Chemotherapy 2014; 23:173-177
doi: 10.3851/IMP2578

Date accepted: 02 April 2013
Date published online: 19 April 2013


Rhinoviruses are extremely common pathogens of the upper respiratory tract with adults experiencing on average 2–5 infections per year and children up to 12 infections. Although infections are not life threatening, except in cases of chronic lung disease where rhinoviruses are the major precipitant of acute exacerbations of disease, there is a high associated economic cost resulting from lost productivity due to absence from work or school. Treatment of infections focuses on symptom relief with anti-pyretics/analgesics as there are no antiviral therapies available and vaccine strategies face difficulties because of the large number of viral serotypes. Here, we assess the potential for prophylactic antibody intervention for these ubiquitous human pathogens.


Copyright © 2020 Nucleus Holdings Ltd. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.